Market capitalization | $2.25b |
Enterprise Value | $1.93b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 21.22 |
P/S ratio (TTM) P/S ratio | 24.72 |
P/B ratio (TTM) P/B ratio | 2.90 |
Revenue growth (TTM) Revenue growth | 12,751.20% |
Revenue (TTM) Revenue | $90.86m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
15 Analysts have issued a Iovance Biotherapeutics Inc forecast:
15 Analysts have issued a Iovance Biotherapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 91 91 |
12,697%
12,697%
|
|
Gross Profit | -18 -18 |
38%
38%
|
|
EBITDA | -388 -388 |
7%
7%
|
EBIT (Operating Income) EBIT | -430 -430 |
4%
4%
|
Net Profit | -410 -410 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Head office | United States |
CEO | Frederick Vogt |
Employees | 557 |
Founded | 2007 |
Website | www.iovance.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.